GlobeNewsWire
29 Jul 2026, 03:38 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
PROCEPT BioRobotics missed its annual revenue guidance by tens of millions of dollars due to an inventory glut of handpieces. — A significant revenue miss combined with systemic inventory mismanagement suggests fundamental operational failures and weakens financial outlook.
-0.80U.S. handpiece unit sales declined nearly 30% sequentially, dropping from 13,225 units in Q3 to 9,400 units. — A sharp sequential decline in core product sales indicates a rapid deceleration in growth or demand.
-0.60A securities class action lawsuit has been filed against PROCEPT BioRobotics alleging the company failed to disclose that handpiece sales materially exceeded procedures. — Legal action alleging fraud and lack of disclosure creates ongoing regulatory risk and potential for significant settlement costs.
-0.40Continue reading
6 related stories
Top 2 movers · tap to explore
The company accumulated cumulative excess field inventory of more than 10,000 units since the first fiscal quarter of 2023. — High excess inventory suggests overproduction or overestimated demand, which often leads to future write-downs.
-0.30Which stocks this story touches
The company is facing a securities fraud class action lawsuit following undisclosed inventory issues and a significant stock price decline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
